Viral oncolysis

Surgical Oncology Clinics of North America

Volumn 11, Issue 3, 2002, Pages 661-680

  Donahue, James M ^a   Mullen, John T ^a   Tanabe, Kenneth K ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CN 706; CV 706; CV 787; FLUOROURACIL; G 207; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOMODULATING AGENT; NV 1020; ONYX 015; PV 701; RRP450; UNCLASSIFIED DRUG;

ADENOVIRUS; ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CELL CLONE; CELL DIVISION; CELL SPECIFICITY; CLINICAL TRIAL; DISEASE MODEL; DNA MODIFICATION; DRUG EFFECT; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; GENETIC ENGINEERING; HERPES SIMPLEX VIRUS 1; HUMAN; HUMAN CELL; IMMUNOMODULATION; MOLECULAR BIOLOGY; MOLECULAR GENETICS; NEWCASTLE DISEASE PARAMYXOVIRUS; NONHUMAN; ONCOGENE; REOVIRUS; REVIEW; TK GENE; TRANSGENE; VACCINIA VIRUS; VIROLOGY; VIRUS CELL INTERACTION;

ADENOVIRIDAE; ANIMALS; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; CLINICAL TRIALS, PHASE III; COMBINED MODALITY THERAPY; DRUG EVALUATION, PRECLINICAL; GENE THERAPY; GENETIC VECTORS; HUMANS; NEOPLASMS; NEWCASTLE DISEASE VIRUS; ONCOGENIC VIRUSES; REOVIRIDAE; SIMPLEXVIRUS; VACCINIA VIRUS; VIRAL PROTEINS; VIRUS REPLICATION;

EID: 0036660818     PISSN: 10553207     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1055-3207(02)00025-X     Document Type: Review

References (72)

1. Cusack Jr JC, Tanabe KK. Cancer gene therapy. Surg Oncol Clin N Am 1998;7:421-69.
2. Dock G. Rabies virus vaccination in a patient with cervical carcinoma. Am J Med Sci 1904;127:563.
3. Sinkovics J, Horvath J. New developments in the virus therapy of cancer: A historical review. Intervirology 1993;36:193.
4. Smith R, Huebner RJ, Rowe WP, Schatten WE, Thomas LB. Studies on the use of viruses in the treatment of carcinoma of the cervix. Cancer 1956;9:1211.
5. Weitzman MD, Wilson JM, Eck SL. Adenovirus vectors in cancer gene therapy. In: Sobol RE, Scanlon KJ, editors. The Internet Book of Gene Therapy. Stamford: Appleton and Lange; 1995. p. 17.
6. Breakefield XO, Kramm CM, Chiocca EA, Pechan PA. Herpes Simplex virus vectors for tumor therapy. In: Sobol RE, Scanlon KJ, editors. The Internet Book of Gene Therapy. Stamford: Appleton and Lange; 1995. p. 41.
7. Moss B. Poxviridae and their replication. In: Fields BN, Knipe DM, editors. Virology. 2nd Edition. New York: Raven Press, Ltd.; 1990. p. 2644.
8. Moss B. Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety. Proc Natl Acad Sci USA 1996;93:11341.
9. Duncan MR, Stanish SM, Cox DC. Differential sensitivity of normal and transformed human cells to reovirus infection. J Virol 1978;28:444.
10. Hashiro G, Loh PC, Yau JT. The preferential cytotoxicity of reovirus for certain transformed cell lines. Arch Virol 1977;54:307.
11. Harrison D, Sauthoff H, Heitner S, Jagirdar J, Rom WN, Hay JG. Wild-type adenovirus decreases tumor xenograft growth, but despite viral persistence complete tumor responses are rarely achieved-deletion of the viral E1b-19-kD gene increases the viral oncolytic effect. Hum Gene Ther 2001;12:1323.
12. Bischoff JR, Kirn DH, Williams A, Heise C, Horn S, Muna M, et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 1996;274:373.
13. Ries SJ, Brandts CH, Chung AS, Biederer CH, Hann BC, Lipner EM, et al. Loss of p14ARF in tumor cells facilitates replication of the adenovirus mutant d11520 (ONYX-015). Nat Med 2000;6:1128.
14. Martuza RL, Malick A, Markert JM, Ruffner KL, Coen DM. Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science 1991;252:854.
15. Goldstein DJ, Weller SK. Factor(s) present in herpes simplex virus type 1 infected cells can compensate for the loss of the large unit of the viral ribonucleotide reductase: Characterization of an ICP6 deletion mutant. Virology 1988;166:41.
16. Goldstein DJ, Weller SK. Herpes simplex virus type 1-induced ribonucleotide reductase activity is dispensable for virus growth and DNA synthesis: Isolation and characterization of an ICP6 1acZ insertion mutant. J Virol 1988;62:196.
17. Carroll NM, Chiocca EA, Takahashi K, Tanabe KK. Enhancement of gene therapy specificity for diffuse colon carcinoma liver metastases with recombinant herpes simplex virus. Ann Surg 1996;224:323.
18. Yoon SS, Carroll NM, Chiocca EA, Tanabe KK. Cancer gene therapy using replication-competent herpes simplex virus type 1. Ann Surg 1998;228:366.
19. Yoon SS, Nakamura H, Carroll NM, Bode BP, Chiocca EA, Tanabe KK. An oncolytic herpes simplex virus type 1 selectively destroys diffuse liver metastases from colon carcinoma. FASEB J 2000;14:301.
20. Chung RY, Saeki Y, Chiocca EA. B-myb promoter retargeting of herpes simplex virus gamma 34.5 gene-mediate virulence toward tumor and cycling cells. J Virol 1999;73:7556.
21. Chou J, Kern ER, Whitley RJ, Roizman B. Mapping of herpes simplex virus-1 neurovirulence to gamma 134.5, a gene nonessential for growth in culture. Science 1990;250:1262.
22. Chou J, Roizman B. The gamma 1(34.5) gene of herpes simplex virus 1 precludes neuroblastoma cells from triggering total shutoff of protein synthesis characteristic of programed cell death in neuronal cells. Proc Natl Acad Sci USA 1992;89:3266.
23. He B, Gross M, Roizman B. The gamma(1)34.5 protein of herpes simplex virus 1 complexes with protein phosphatase lalpha to dephosphorylate the alpha subunit of the eukaryotic translation initiation factor 2 and preclude the shutoff of protein synthesis by double-stranded RNA-activated protein kinase. Proc Natl Acad Sci USA 1997;94:843.
24. I34.5 expression and oncolysis of diffuse liver metastases by Myb34.5. J Clin Invest 2001, in press.
25. Naik AM, Xu H, Alexander HR, Bartlett DL. A mutant vaccinia virus with improved tumor selectivity. Presented at the 54th Annual SSO Cancer Symposium: March, 2001. Washington, D.C.
26. Buller RM, Smith GL, Cremer K, Notkins AL, Moss B. Decreased virulence of recombinant vaccinia virus expression vectors is associated with a thymidine kinase-negative phenotype. Nature 1985;317:813.
27. Puhlmann M, Brown CK, Gnant M, Huang J, Libutti SK, Alexander HR, et al. Vaccinia as a vector for tumor-directed gene therapy: Biodistribution of a thymidine kinase-deleted mutant. Cancer Gene Ther 2000;7:66.
28. Coffey MC, Strong JE, Forsyth PA, Lee PWK. Reovirus therapy of tumors with activated ras pathway. Science 1998;282:1332.
29. Strong JE, Coffey MC, Tang D, Sabinin P, Lee PWK. The molecular basis of viral oncolysis: Usrpation of the ras signaling pathway by reovirus. EMBO J 1998;17:3351.
30. Strong JE, Lee PW. The v-erbB oncogene confers enhanced cellular susceptibility to reovirus infection. J Virol 1996;70:612.
31. Hirasawa K, Yoon C, Nishikawa SG, Waisman DM, Lee PWK. Reovirus therapy of metastatic cancer models in immune-competent mice. In: Proceedings of the American Association of Cancer Research. 92nd Annual Meeting. March 2001. New Orleans (LA). p. 2437a.
32. Hallenbeck PL, Chang YN, Hay C, Golightly D, Stewart D, Lin J, et al. A novel tumor-specific replication-restricted adenoviral vector for gene therapy of hepatocellular carcinoma. Hum Gene Ther 1999;1:1721.
33. Kurihara T, Brough DE, Kovesdi I, Kufe DW. Selectivity of a replication-competent adenovirus for human breast carcinoma cells expressing the MUC1 antigen. J Clin Invest 2000;106:763.
34. DeVita VT. Principles of chemotherapy. In: DeVita VTJ, Hellman S, Rosenberg SA, editors. Cancer. Principles and Practice of Oncology. Philadelphia: J.B. Lippincott Co.; 1993. p. 276.
35. Kaufman D, Chabner BA. Clinical strategies for cancer treatment: The role of drugs. In: Chabner BA, Longo DL, editors. Cancer Chemotherapy and Biotherapy. Philadelphia: Lippincott-Raven; 1996. p. 1.
36. Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, Fisher DE, et al. p53 status and the efficacy of cancer therapy in vivo. Science 1994;266:807.
37. Ganly I, Eckhardt SG, Rodriguez GI, Soutar DS, Otto R, Robertson AG, et al. A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer. Clin Cancer Res 2000;6:798.
38. Sanchez-Prieto R, Quintanilla M, Cano A, Leonart ML, Martin P, Anaya A, et al. Carcinoma cell lines become sensitive to DNA-damaging agents by the expression of the adenovirus EIA gene. Oncogene 1996;13:1083.
39. Bradley JD, Kataoka Y, Advani S, Chung SM, Arani RB, Gillespie GY, et al. Ionizing radiation improves survival in mice bearing intracranial high-grade gliomas injected with genetically modified herpes simplex virus. Clin Cancer Res 1999;5:1517.
40. Bi WL, Parysek LM, Warnick R, Stambrook PJ. In vitro evidence that metabolic cooperation is responsible for the bystander effect observed with HSV tk retroviral gene therapy. Hum Gene Ther 1993;4:725.
41. Chen CY, Chang YN, Ryan P, Linscott M, McGarrity GJ, Chiang YL. Effect of herpes simplex virus thymidine kinase expression levels on ganciclovir- mediated cytotoxicity and the "bystandereffect." Hum Gene Ther 1995;6:1467.
42. Freeman SM, Abboud CN, Whartenby KA, Packman CH, Koeplin DS, Moolten FL, et al. The "bystander effect": Tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res 1993;53:5274.
43. Ichikawa T, Chiocca EA. Comparative analyses of transgene delivery and expression in tumors inoculated with a replication-conditional or -defective viral vector. Cancer Res 2001;61:5336.
44. Nakamura H, Mullen JT, Chandrasekhar S, Pawlik TM, Yoon SS, Tanabe KK. Multimodality therapy with a replication-conditional herpes simplex virus 1 mutant that expresses yeast cytosine deaminase for intratumoral conversion of 5-fluorocytosine to 5-fluorouracil. Cancer Res 2001;61:5447.
45. Chase M, Chung R, Chiocca EA. An oncolytic viral mutant that delivers the CYP2B1 transgene and augments cyclophosphamide chemotherapy. Nat Biotech 1998;16:444.
46. Clarke L, Waxman DJ. Oxidative metabolism of cyclophosphamide: Identification of the hepatic monooxygenase catalysts of drug activation. Cancer Res 1989;49:2344.
47. Pawlik TM, Nakamura H, Yoon SS, Mullen JT, Chandrasekhar S, Chiocca EA, et al. Oncolysis of diffuse hepatocellular carcinoma by intravascular administration of a replication-competent, genetically engineered herpesvirus. Cancer Res 2000;60:2790.
48. Puhlmann M, Gnant M, Brown CK, Alexander HR, Bartlett DL. Thymidine kinase-deleted vaccinia virus expressing purine nucleoside phosphorylase as a vector for tumor-directed gene therapy. Hum Gene Ther 1999;10:649.
49. Gnant MFX, Puhlmann M, Alexander HR, Bartlett DL. Systemic administration of a recombinant vaccinia virus expressing the cytosine deaminase gene and subsequent treatment with 5-fluorocytosine leads to tumor-specific gene expression and prolongation of survival in mice. Cancer Res 1999;59:3396.
50. Carroll NM, Chiocca EA, Tanabe KK. The effect of ganciclovir on herpes simlex virus-mediated oncolysis. J Surg Res 1997;69:413.
51. Ikeda K, Ichikawa T, Wakimoto H, Silver J, Deisboeck T, Lewis DN, et al. Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited anti-viral responses. Nat Med 1999;5:881.
52. Delman KA, Bennett JJ, Zager JS, Burt BM, McAuliffe PF, Petrowsky H, et al. Effects of pre-existing immunity on the response to herpes simplex-based oncolytic viral therapy. Hum Gene Ther 2000;11:2465.
53. Toda M, Rabkin SD, Kojima H, Martuza RL. Herpes simplex virus as an in situ cancer vaccine for the induction of specific antitumor immunity. Hum Gene Ther 1999;10:385.
54. Habib NA, Sarraf CE, Mitry RR, Havlik R, Nicholls J, Kelly M, et al. E1B-deleted adenovirus (d/1520) gene therapy for patients with primary and secondary liver tumors. Hum Gene Ther 2001;12:219.
55. Reid TR, Galanis E, Abbruzzese J, Sze D, Andrews J, Randlev B, et al. Intra-arterial administration of a replication-selective adenovirus Ci-1042 (Onyx-015) in patients with colorectal carcinoma metastatic to the liver: Safety, feasibility and biological activity. Proc Am Soc Clin Oncol 2001;20:549a.
56. Heise C, Ganly I, Kim YT, Sampson-Johannes A, Brown R, Kirn D. Efficacy of a replication-selective adenovirus against ovarian carcinomatosis is dependent on tumor burden, viral replication and p53 status. Gene Ther 2000;7:1925.
57. Rodriguez R, Schuur ER, Lim HY, Henderson GA, Simons JW, Henderson DR. Prostate attenuated replication competent adenovirus (ARCA) CN706: A selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. Cancer Res 1997;57:2559.
58. Lamont JP, Nemunaitis J, Kuhn JA, Landers SA, McCarty TM. A prospective phase II trial of ONYX-015 adenovirus and chemotherapy in recurrent squamous cell carcinoma of the head and neck (the Baylor experience). Ann Surg Oncol 2000;7:588.
59. Nemunaitis J, Khuri F, Ganly I, Arseneau J, Posner M, Vokes E, et al. Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer. J Clin Oncol 2001;19:289.
60. Khuri FR, Nemunaitis J, Ganly I, Arseneau J, Tannock IF, Romel L, et al. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med 2000;6:879.
61. Hunter WD, Martuza RL, Feigenbaum F, Todo T, Mineta T, Yazaki T, et al. Attenuated, replication-competent herpes simplex virus type I mutant G207: Safety evaluation of intracerebral injection in nonhuman primates. J Virol 1999;73:6319.
62. Markert JM, Medlock MD, Rabkin SD, Gillespie GY, Todo T, Hunter WD, et al. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial [comments]. Gene Ther 2000;7:867.
63. Meignier B, Longnecker R, Roizman B. In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020: Construction and evaluation in rodents. J Infect Dis 1988;158:602.
64. Wallack MK, Sivanandham M, Balch CM, Urist MM, Bland KI, Murray D, et al. Surgical adjuvant active specific immunotherapy for patients with stage III melanoma: The final analysis of data from a phase III, randomized, double-blind, multicenter vaccinia melanoma oncolysate trial. J Am Coll Surg 1998;187:69.
65. Mastrangelo MJ, Maguire Jr HC, Eisenlohr LC, Laughlin CE, Monken CE, McCue PA, et al. Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma. Cancer Gene Ther 1999;6:409.
66. Flanagan AD, Lover R, Tesar W. Propagation of Newcastle disease virus in Ehrlich ascites cells in vitro and in vivo. Proc Soc Exp Biol Med 1955;90:82.
67. Lorence RM, Reichard KW, Katubig BB, Reyes HM, Phuangsab A, Mitchell BR, et al. Complete regression of human neuroblastoma xenografts in athymic mice after local Newcastle disease virus therapy. J Natl Cancer Inst 1994;86:1228.
68. Reichard KW, Lorence RM, Cascino CJ, Peeples ME, Walter RJ, Fernando MB, et al. Newcastle disease virus selectively kills human tumor cells. J Surg Res 1992;52:448.
69. Batliwalla FM, Bateman BA, Serrano D, Murray D, Macphail S, Maino VC, et al. A 15-year follow-up of AJCC stage III malignant melanoma patients treated postsurgically with Newcastle disease virus (NDV) oncolysate and determination of alterations in the CD8 T cell repertoire. Mol Med 1998;4:783.
70. Roberts MS. Buasen PT, Incao BA, Groene WS, Duhon CS, McDaniel GP, et al. P701, a naturally attenuated strain of Newcastle disease virus has a broad spectrum of oncolytic activity against human tumor xenografts. In: Proceedings of the American Association of Cancer Research. March 2001. New Orleans (LA). p. 2437a.
71. Lorence RM, Roberts MS, Groene WS, Buasen PT, Incao BA, Rabin H. Regression of human tumor xenografts following intravenous treatment using PV701, a naturally attenuated oncolytic strain of Newcastle disease virus. In: Proceedings of the American Association of Cancer Research. March 2001. New Orleans (LA). p. 2437a.
72. Pecora AL, Rizvi N, Cohen GI. An intravenous phase I trial of a replication-competent virus, PV701, in the treatment of patients with advanced solid cancers. In: Proceedings of the American Society of Clinical Oncology. 37th Annual Meeting. May 2001. Sanfrancisco (CA). p. 1009a.